Subject : A Survey to understand the prescribing pattern of statins and combination for management of dyslipidemia in patients for primary or secondary prevention of ASCVD (BEAT-Survey)
Cardio vascular diseases (CVD) have become a growing burden across the globe and are highly prevalent, especially in the developing countries that alone account for 80% of the global CVD mortality. Dyslipidemia has been strongly associated with the pathophysiology of cardiovascular diseases (CVDs) and is a major independent risk factor for coronary artery disease (CAD), and associated cardiovascular events.
The prevalence of dyslipidemia varies geographically; although, it has been estimated that more than 50% of the adult population has dyslipidemia worldwide. Studies have shown that Asians have a higher prevalence of lipid abnormalities as compared to non- Asians, it has been observed that dyslipidemia in Asians, especially Indians, is atherogenic, with a higher prevalence of low HDL cholesterol and high triglycerides and a lower prevalence of high serum cholesterol
Statins have been shown to reduce atherosclerosis cardiovascular disease events in both secondary and primary prevention. Statins have a limited ability to impact the levels of triglycerides, high-density lipoprotein cholesterol (HDL-C), and conditional coronary heart disease risk factors such as C-reactive protein and lipoprotein A. This provides a rationale to consider the addition of other lipid-modifying agents in the treatment of patients with complex dyslipidemia and/or at high risk for coronary heart disease. Additionally, the addition of such agents may offer the opportunity to augment the LDL-lowering effects of statins to attain the desirable LDL-C targets. Additionally in secondary prevention, apart from statins the anti-platelets are also the pillars in managing ACS patient.
The major challenge for use of cholesterol-lowering drugs is the problem of long-term non-adherence. Improving adherence will require fundamental changes in the current healthcare system in which patient monitoring and follow-up is often not a high priority.
The purpose of this survey is to understand the prescribing pattern of statins and their combinations by cardiologist and physicians for primary & secondary prevention of cardiovascular disease in patient with/without dyslipidaemia and the role played by antiplatelets (SAPT and/or DAPT therapy).
The survey analysis will help Sun Pharmaceutical Laboratories Ltd to strengthen the continuous medical education activities, understand the need of evidence generation and requirement of patient support programs if any.
We invite you to participate in this survey. On acceptance, you will need to provide relevant responses on the survey form which is enclosed herewith.
We thank you in advance for your support and giving your valuable time to complete the survey questionnaire.
|
}}){kind=logo}